HealthEquity, Inc. (NASDAQ:HQY) Given Consensus Rating of “Moderate Buy” by Analysts

HealthEquity, Inc. (NASDAQ:HQY) has earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $110.9286.

A number of brokerages have issued reports on HQY. BTIG Research upped their target price on HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Barrington Research restated an “outperform” rating and issued a $110.00 price target on shares of HealthEquity in a research note on Friday, May 22nd. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. Citizens Jmp boosted their target price on shares of HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research report on Monday, June 1st. Finally, Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th.

Insiders Place Their Bets

In other HealthEquity news, Director Adrian T. Dillon sold 7,632 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the transaction, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 12,456 shares of company stock valued at $1,256,664. 1.60% of the stock is owned by company insiders.

Institutional Trading of HealthEquity

Large investors have recently modified their holdings of the company. Acumen Wealth Advisors LLC acquired a new position in HealthEquity during the 4th quarter valued at about $27,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of HealthEquity in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its stake in shares of HealthEquity by 1,723.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after purchasing an additional 293 shares during the period. Leonteq Securities AG raised its holdings in shares of HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock valued at $32,000 after buying an additional 235 shares during the last quarter. Finally, Silvant Capital Management LLC bought a new stake in shares of HealthEquity during the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Stock Down 10.6%

Shares of NASDAQ HQY opened at $93.39 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44. HealthEquity has a 1 year low of $72.76 and a 1 year high of $107.62. The stock’s 50-day simple moving average is $97.93 and its 200-day simple moving average is $87.81. The firm has a market cap of $7.81 billion, a price-to-earnings ratio of 34.98, a PEG ratio of 1.76 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. The business’s quarterly revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, equities analysts anticipate that HealthEquity will post 3.92 earnings per share for the current fiscal year.

More HealthEquity News

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted EPS of $1.24 versus the $1.19 consensus and revenue of $350.7 million versus $349.2 million. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved: net income rose 10% to $65.6 million, net margin expanded to 19% from 18%, and adjusted EBITDA increased 11% to $167 million, with the EBITDA margin rising to 48% from 46%. HealthEquity Reports Second Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. HSA assets reached a record $37.9 billion, supporting HealthEquity’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Neutral Sentiment: Revenue guidance was approximately $1.4 billion, broadly in line with analysts’ expectations, meaning the guidance increase was concentrated primarily in earnings rather than sales.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares worth approximately $798,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add short-term selling pressure. Adrian T. Dillon Insider Transaction
• Negative Sentiment: At roughly 35 times earnings, HQY remains priced for substantial growth. Investors may be using the strong report as an opportunity to lock in gains, particularly after the shares traded near their 52-week high.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.